← ANALYST RATINGS · TIPRANKS
Pacific Biosciences (PACB): analyst forecast and price target
Analyst consensus
Hold2 Buy2 Hold1 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $1.90, the highest $3.00, the lowest $1.25. The average is +9.8% from the last price of $1.73.
Analyst ratings 8
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | +15.6% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Hold | +15.6% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | +15.6% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Hold | +15.6% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | +15.6% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $3.00 → $2.50−16.7% | Hold | +44.5% | Reiterated | 09.10.26on TipRanks 01:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $3.00 → $2.50−16.7% | Hold | +44.5% | Reiterated | 09.10.26on TipRanks 01:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $3.00 → $2.50−16.7% | Hold | +44.5% | Reiterated | 09.10.26on TipRanks 01:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $3.00 → $2.50−16.7% | Hold | +44.5% | Reiterated | 09.10.26on TipRanks 01:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $3.00 → $2.00−33.3% | Hold | +15.6% | Reiterated | 09.10.26on TipRanks 01:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $2.50−16.7% | Hold | +44.5% | Reiterated | 09.10.26on TipRanks 01:05 | — | |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $1.25 | Sell | −27.7% | Reiterated | 07.10.26on TipRanks 04:00 | +1.0%next day −15.0% · 5 days −25.9% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $2.50 → $3.00+20.0% | Hold | +73.4% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $2.50 → $3.00+20.0% | Hold | +73.4% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $2.50 → $3.00+20.0% | Hold | +73.4% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $2.50 → $3.00+20.0% | Hold | +73.4% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $2.50 → $3.00+20.0% | Hold | +73.4% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $3.00+20.0% | Hold | +73.4% | Reiterated | 06.10.26on TipRanks 05:05 | — | |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $2.00 → $2.50+25.0% | Hold | +44.5% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $2.00 → $2.50+25.0% | Hold | +44.5% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $2.00 → $2.50+25.0% | Hold | +44.5% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $2.00 → $2.50+25.0% | Hold | +44.5% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $2.00 → $2.50+25.0% | Hold | +44.5% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $2.50+25.0% | Hold | +44.5% | Reiterated | 01.10.26on TipRanks 03:05 | — | |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $1.50 → $2.00+33.3% | Hold | +15.6% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $1.50 → $2.00+33.3% | Hold | +15.6% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $1.50 → $2.00+33.3% | Hold | +15.6% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $1.50 → $2.00+33.3% | Hold | +15.6% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $1.50 → $2.00+33.3% | Hold | +15.6% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 → $2.00+33.3% | Hold | +15.6% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | — | Buy | — | Reiterated | 11.09.26on TipRanks 04:05 | +1.5%next day +4.3% · 5 days +5.5% | ↗ |
| Unknown Analyst | UBS | $1.50 → $1.35−10.0% | Hold | −22.0% | Initiated | 08.09.26on TipRanks Sep 10 23:05 | −1.7%next day −1.8% · 5 days +2.6% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $2.00 | Hold | +15.6% | Reiterated | 06.08.26on TipRanks 07:01 | −10.2%next day +1.1% · 5 days −2.5% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $3.00 | Buy | +73.4% | Reiterated | 06.08.26on TipRanks 05:50 | −10.2%next day +1.1% · 5 days −2.5% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $1.25 | Sell | −27.7% | Reiterated | 05.08.26on TipRanks Aug 20 04:25 | −9.5%next day −10.2% · 5 days −15.0% | |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | — | Hold | — | Reiterated | 12.02.26on TipRanks Feb 16 07:40 | +1.5%next day −7.1% · 5 days −13.7% | ↗ |
| Mason Carrico★★★★★★★★★★#10833 · hits 38% · avg −4.7% | Stephens | $1.80 → $2.00+11.1% | Buy | +15.6% | Reiterated | 10.11.25on TipRanks 06:45 | −1.6%next day +5.5% · 5 days −8.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Pacific Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $1.90 at a price of $2.37 (−19.8%); now: $1.90 at $1.73 (+9.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 3 | 2 | 1 | 1 | 1 | 2 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.14 to $-0.12). Last quarter: $-0.14.
Sales
Next quarter’s sales estimate — $39M (from $37M to $42M). Last quarter: $39M.
Best top-analyst consensus in the sector · Healthcare
About Pacific Biosciences
- CEO: Mark Van Oene
- Employees: 485
- 1305 O’Brien Drive, Menlo Park, CA, 94025, US
- www.pacb.com
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Data from the stock’s TipRanks forecast page, read 76 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗